BioPharma Services Inc.’s Post

The management of lung cancer (LC) requires the analysis of a diverse spectrum of molecular targets, including kinase activating mutations in EGFR, ERBB2 (HER2), BRAF and MET oncogenes, KRAS G12C substitutions, and ALK, ROS1, RET and NTRK1-3 gene fusions. Administration of immune checkpoint inhibitors (ICIs) is based on the immunohistochemical (IHC) analysis of PD-L1 expression and determination of tumor mutation burden (TMB). Clinical characteristics of the patients, particularly age, gender and smoking history, significantly influence the probability of finding the above targets: for example, LC in young patients is characterized by high frequency of kinase gene rearrangements, while heavy smokers often have KRAS G12C mutations and/or high TMB. Proper selection of first-line therapy influences overall treatment outcomes, therefore, the majority of these tests need to be completed within no more than 10 working days. Activating events in MAPK signaling pathway are mutually exclusive, hence, fast single-gene testing remains an option for some laboratories. RNA next-generation sequencing (NGS) is capable of detecting the entire repertoire of druggable gene alterations, therefore it is gradually becoming a dominating technology in LC molecular diagnosis. 🎬 Current status of molecular diagnostics for lung cancer 📝 Authors: Evgeny N. Imyanitov *, Elena V. Preobrazhenskaya, Sergey V. Orlov 📚 This article belongs to the special issue Integrated Approaches for Non-Small-Cell Lung Cancer 👨⚕️Guest Editor: Prof. Dr. Alessandro Morabito and Dr. Edoardo Mercadante, MD, PhD 🏃♂️ Welcome to read, forward, and share the article! https://lnkd.in/gQi54-BK 📄 PDF: https://lnkd.in/gXBYEZy8 #LungCancer #Mutations #Fusions #PredictiveMarkers #Therapy

𝗨𝗻𝗰𝗼𝘃𝗲𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺 𝗼𝗳 𝗩𝗮𝗹𝗲𝗺𝗲𝘁𝗼𝘀𝘁𝗮𝘁: 𝗔 𝗡𝗲𝘄 𝗛𝗼𝗽𝗲 𝗶𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 Researchers identified the mechanism of the cancer drug valemetostat and established its efficacy in treating adult T-cell leukemia/lymphoma.   👉 The development of epigenetic therapeutics has promise for cancer treatment. One promising drug is valemetostat. Essentially, valemetostat prevents the methylation of histone H3 by inhibiting the histone-modifying enzymes EZH1 and EZH2. 👉 A study published in 𝘕𝘢𝘵𝘶𝘳𝘦 aimed to better understand the mechanism and efficacy of valemetostat. Researchers conducted single-cell gene sequencing on samples taken from adults given valemetostat to treat Tcell-leukaemia/lymphoma, a rare type of blood cancer. The study revealed that the drug leads to the reprogramming of the cancer epigenome, abolishing the highly condensed chromatin structure formed by the tri-methyl-histone H3. This results in several tumor suppressor genes becoming accessible for expression and thereby the inhibItion of tumor cell growth. This study represents a significant step forward in the field of epigenetic cancer treatments, a hope for more personalized treatment.    #cancerresearch #drug #lymphoma #epigenome #epigenetics #medicine #biology https://lnkd.in/eDAxKJj5

Annexins and cancer Antibody to annexin A1 (AnxA1) halts cancer cell proliferation in vitro and in vivo. Cell cycle arrested in G1 phase. Already established that Knockout of AnxA2 gene targets metastasis by reducing membrane repair of cells in the circulation. Annexin “therapies” look more and more interesting .. #annexin #AnxA1 #proliferation #metastasis #cellcycle #therapies

Lung Cancer Clinical Trials Yield Positive Patient Outcomes in Genprex, Inc.'s New Video Update Featuring Chief Medical Officer Genprex, Inc. shared promising updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials for lung cancer in a video featuring Chief Medical Officer Dr. Mark Berger. The Acclaim-1 trial evaluates Genprex, Inc.'s Reqorsa® Gene Therapy in combination with AstraZeneca's Tagrisso® for patients with late-stage non-small cell lung cancer who have EGFR mutations. The Acclaim-3 trial examines Reqorsa with Genentech's Tecentriq® as maintenance therapy for patients with extensive-stage small cell lung cancer. Genprex, Inc. has refined its clinical development strategy by streamlining the Acclaim-1 trial and closing the Acclaim-2 study to focus on the most promising outcomes. Dr. Berger emphasized the potential of Reqorsa to improve lung cancer treatment and enhance patient quality of life, as the company advances toward bringing this innovative therapy to market. For more details please click the link! https://lnkd.in/d6xP4zxr #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

Phenotypic plasticity is a cancer hallmark, and lung adeno-to-squamous transition (AST) triggered by LKB1 inactivation is significantly associated with drug resistance. Clinical data show that squamous transition occurs in certain lung adenocarcinoma patients who relapse from targeted therapy using EGFR tyrosine-kinase inhibitors (TKIs) or KRAS inhibitor. However, the epigenetic regulatory mechanisms involved in AST remain largely unknown. - TET2-STAT3-CXCL5 nexus promotes neutrophil lipid transfer to fuel lung adeno-to-squamous transition - Tet2 knockout in KrasG12D;Lkb1-/- (KL) model suppresses squamous transition through immune microenvironment remodeling - TET2 is recruited to Cxcl5 promoter region via the interaction with STAT3, resulting in Cxcl5 promoter demethylation and gene expression - Therapeutic strategies to control AST process include targeting STAT3 activation, reducing CXCL5 level, or blocking lipid transfer - Study uncovers epigenetic mechanism orchestrating phenotypic plasticity through regulating immune microenvironment and metabolic communication What are your thoughts on the potential therapeutic strategies identified in this study to inhibit lung cancer transition? #medicalinnovation #cancerresearch #lungcancer #sciencex

🔬💊 Revolutionizing Pancreatic Cancer Treatment: The Power of Patient-Derived Organoids Pancreatic cancer poses a formidable challenge in the medical world, having the highest mortality rate among major cancers. But what if miniature models of a patient's tumor could change the game? Enter patient-derived organoids, a cutting-edge biotechnology offering a personalized approach to treatment. Researchers at the Salk Institute recently shed light on the reliability of these organoids in mimicking pancreatic tumors. Their study, published in JCI Insight, revealed that the choice of extracellular matrix—the scaffold for growing these organoids—didn't significantly alter gene expression or drug responses. However, one brand did accelerate organoid growth, an advantage for the urgency in pancreatic cancer treatment. Dr. Dannielle Engle, the study's senior author, emphasizes the importance of personalized medicine. With organoids, clinicians gain a predictive model to tailor treatments effectively, sparing patients from the "guessing game" of traditional approaches. While variations in culture media can influence organoid behavior, differences in extracellular matrices had minimal impact. This discovery strengthens confidence in organoid technology's accuracy and reliability for evaluating patient drug responses. With continued optimization and validation, these organoids hold promise in improving patient outcomes.   « Together, we're inching closer to a future where pancreatic cancer is no longer a death sentence » For further information, check the following paper.  https://lnkd.in/eKP-wwJ4

Exciting Research Update on Pancreatic Ductal Adenocarcinoma (PDAC)! I'm thrilled to share our latest preprint on bioRxiv, where we explore a promising combination therapy for PDAC, a cancer notorious for its resistance to current chemotherapies. Our study tackles the challenge of personalized therapy in PDAC by focusing on tumors dependent on KRAS for survival (dKRAS). We discovered that gene expression signature scores can effectively assess KRAS dependency, opening doors to tailored treatments. Findings: KRAS Dependency: Nearly 90% of PDAC cases harbor KRAS mutations. Our transcriptomic-based KRAS dependency scores can predict the efficacy of targeted therapies. Combination Therapy: We found that combining low-dose decitabine (DEC) with the PARP inhibitor olaparib (OLA) significantly enhances antitumor activity in dKRAS-PDAC. This synergy is due to DEC inducing DNA damage and activating a DNA damage response, which is further exploited by inhibiting PARP with OLA. Broader Efficacy: This combination is effective even in BRCA1/2 wild-type and homologous recombination-proficient tumors, extending the clinical benefit of OLA beyond BRCA status. Metastasis Inhibition: In dKRAS-PDAC tumors with a BRCA2 mutation, DEC+OLA inhibited metastasis growth, outperforming single-drug treatments. These findings underscore the potential of DEC+OLA combination therapy in PDAC, highlighting DNA damage response as a critical mechanism and advocating for its clinical evaluation irrespective of BRCA1/2 status. Read the full preprint here: https://lnkd.in/dTsM8kri Thank you to my incredible team and collaborators for contributing to this research. We believe this approach could pave the way for more effective and personalized treatments for PDAC patients. #PancreaticCancer #PDAC #KRAS #CancerResearch #PersonalizedMedicine #bioRxiv #Research #Oncology #CancerTherapy

🔬 New Insights in Cancer Therapy: siRNA Delivery through PLANAS 🔬 I am pleased to announce my latest Medium article exploring a promising advancement in cancer treatment: siRNA Delivery via PLANAs: Revolutionizing Cancer Gene Silencing In this article, I delve into the potential of small interfering RNA (siRNA) in gene silencing and detail the innovative PLANAS delivery system developed by Hall et al. This system significantly enhances the cellular uptake and efficacy of siRNA, particularly against challenging cancer types such as triple-negative breast cancer. 📝 Key Highlights: - Detailed explanation of siRNA mechanisms - Comprehensive overview of the PLANAs formulation with peptides and lipids - Findings from Hall et al.'s recent studies demonstrating PLANAs' efficacy This article offers an in-depth look at cutting-edge research that could pave the way for new therapeutic strategies in oncology. 📖 Read the full article here: https://lnkd.in/eyNbE-4Q #CancerResearch #siRNA #Pharmaceutics #Biotechnology #HealthcareInnovation #CancerTherapy #ScientificResearch #MediumArticle

As colorectal cancer (CRC) continues to challenge us with its prevalence and drug resistance, particularly in younger patients, the spotlight turns to new therapeutic targets like LY6G6D. Found within the MHC III gene cluster, LY6G6D plays a role in tumor cell growth, especially in cancer types that tend to metastasize and resist drugs. It's overexpressed in pMMR/MSS CRC, marking it as a promising target for novel treatments. KACTUS is at the forefront, offering high-quality recombinant LY6G6D proteins to accelerate the development of targeted therapeutics. Dive into the potential of LY6G6D 👉🏻 https://bit.ly/496n2wA #CancerTherapy #InnovativeResearch #KACTUS #ColorectalCancer #CRC #LY6G6D #TargetedTherapy #DrugDevelopment #Biotechnology